Related Experiment Video
Updated: May 6, 2026
09:13
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
1.4K
The principles of PK-tailored prophylaxis
1Prof. Dr. med. Armin J. Reininger, Baxter Innovations GmbH, Industriestr. 67, 1220 Vienna, Austria, Tel. +43/1/201 00-247 34 94 Fax +43/1/201 00-530,
Hamostaseologie
|October 31, 2013
Summary
Pharmacokinetic-tailored prophylaxis using recombinant factor VIII (rFVIII) significantly reduced bleeds and improved quality of life in severe haemophilia A patients. This personalized approach may offer a viable alternative to standard prophylaxis regimens.
Area of Science:
- Hematology
- Pharmacokinetics
- Clinical Trials
Background:
- Severe haemophilia A treatment often involves factor VIII (FVIII) prophylaxis, but optimal regimens remain debated.
- Standard prophylaxis may not be universally effective or personalized to individual patient needs.
- Recombinant FVIII (rFVIII) products offer potential for tailored treatment strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of a pharmacokinetic (PK)-tailored prophylaxis regimen with rFVIII (ADVATE).
- To assess the impact of PK-tailored prophylaxis on annual bleed rates (ABR) and health-related quality of life.
- To identify open questions regarding the implementation of PK-tailored prophylaxis in clinical practice.
Main Methods:
- A study was conducted using a PK-tailored prophylaxis regimen with rFVIII (ADVATE).
- The regimen aimed to maintain FVIII trough levels of at least 1%.
- Outcomes measured included annual bleed rate (ABR) and quality of life using the SF-36v1 questionnaire.
Main Results:
- PK-tailored prophylaxis significantly reduced the annual bleed rate (ABR) compared to on-demand treatment (p < 0.0001).
- Bodily pain, a key quality of life indicator, significantly improved (p = 0.0007).
- The safety and efficacy of this individualized approach were demonstrated.
Conclusions:
- PK-tailored prophylaxis with ADVATE presents a potentially effective alternative to standard prophylaxis for severe haemophilia A.
- Further research is needed to determine optimal FVIII trough levels for preventing all bleeds, especially in patients with target joints.
- Development of user-friendly tools for calculating individualized PK-driven prophylaxis is crucial for widespread implementation.
Related Concept Videos
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
129
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
129
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
562
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
562
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
366
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
366
01:26Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
270
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
270
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
235
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
235
01:28Dosage Regimens: Designs and Approaches
605
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
605